Journal article icon

Journal article

VCAM-1 targeted magnetic resonance imaging enables detection of brain micrometastases from different primary tumours

Abstract:
Purpose: A major issue for the effective treatment of brain metastasis is the late stage of diagnosis with existing clinical tools. The aim of this study was to evaluate the potential of vascular cell adhesion molecule-1 (VCAM-1) targeted magnetic resonance imaging (MRI) for early detection of brain micrometastases in mouse models across multiple primary tumour types. Experimental Design: Xenograft models of brain micrometastasis for human breast carcinoma (MDA231Br-GFP), lung adenocarcinoma (SEBTA-001) and melanoma (H1_DL2) were established via intracardiac injection in mice. Animals (n=5-6/group) were injected intravenously with VCAM-1 targeted microparticles of iron oxide (VCAM-MPIO) and, subsequently, underwent T2*-weighted MRI. Control groups of naïve mice injected with VCAM-MPIO and tumour-bearing mice injected with non-targeting IgG-MPIO were included. Results: All models showed disseminated micrometastases in the brain, together with endothelial VCAM-1 upregulation across the time-course. T2*-weighted MRI of all tumour-bearing mice injected with VCAM-MPIO showed significantly more signal hypointensities (p<0.001; two-sided) than control cohorts, despite a lack of blood-brain barrier impairment. Specific MPIO binding to VCAM-1 positive tumour-associated vessels was confirmed histologically. VCAM-1 expression was demonstrated in human brain metastasis samples, across all three primary tumour types. Conclusions: VCAM-1-targeted MRI enables detection of brain micrometastases from the three primary tumour types known to cause the majority of clinical cases. These findings represent an important step forward in the development of a broadly applicable and clinically relevant imaging technique for early diagnosis of brain metastasis, with significant implications for improved patient survival.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1158/1078-0432.CCR-18-1889

Authors

More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Sub department:
CRUK/MRC Ox Inst Radiation Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Sub department:
CRUK/MRC Ox Inst Radiation Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Sub department:
CRUK/MRC Ox Inst Radiation Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Sub department:
CRUK/MRC Ox Inst Radiation Oncology
Role:
Author


More from this funder
Funding agency for:
Soto, M
Funding agency for:
Khrapitchev, A
Funding agency for:
Balderas, F
Funding agency for:
Sibson, N
Grant:
C5255/A15935
Grant:
C5255/A15935
Grant:
C5255/A15935
Grant:
C5255/A15935
More from this funder
Funding agency for:
Cheng, VWT
Grant:
Clinical research fellowship


Publisher:
American Association for Cancer Research
Journal:
Clinical Cancer Research More from this journal
Volume:
25
Issue:
2
Publication date:
2018-11-02
Acceptance date:
2018-10-30
DOI:
EISSN:
1557-3265
ISSN:
1078-0432


Keywords:
Pubs id:
pubs:937120
UUID:
uuid:3eaa73a4-cc50-4f95-9034-f7dbaf31fbdb
Local pid:
pubs:937120
Source identifiers:
937120
Deposit date:
2018-11-05
ARK identifier:

Terms of use


Views and Downloads

Views and downloads will return soon






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP